Product

7+3

Aliases

7+3 (cytarabine and daunorubicin)

1 clinical trial

1 indication

Indication

High-risk (Secondary) Acute Myeloid Leukemia

Clinical trial

A Randomized, Multi-center, Open-label Phase III Bridging Study to Compare Efficacy of Liposomal Cytarabine-Daunorubicin for Injection With Cytarabine and Daunorubicin in Treating Older Patients With High-Risk (Secondary) Acute Myeloid Leukemia

Status: Not yet recruiting, Estimated PCD: 2026-02-01